• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Genmab

1,594.00 DKK

-1.54 %

Less than 1K followers

GMAB

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-1.54 %
-5.34 %
-6.37 %
-21.36 %
-20.89 %
+7.63 %
-40.19 %
-41.03 %
+4,574.49 %

Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.

Read more
Market cap
99.39B DKK
Turnover
153.99M DKK
Revenue
23.65B
EBIT %
28.63 %
P/E
16.17
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
6/8
2026

Interim report Q2'26

5/11
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release5 hours ago

Major Shareholder Announcement

Genmab
Press release6/13/2026, 4:45 PM

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab
Regulatory press release6/11/2026, 5:16 PM

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release6/11/2026, 2:45 PM

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Genmab
Regulatory press release5/29/2026, 8:34 PM

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Genmab
Press release5/21/2026, 9:00 PM

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

Genmab
Regulatory press release5/12/2026, 5:46 PM

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab
Regulatory press release5/8/2026, 7:05 PM

Major Shareholder Announcement

Genmab
Regulatory press release5/7/2026, 3:01 PM

Genmab Announces Financial Results for the First Quarter of 2026

Genmab
Regulatory press release4/17/2026, 2:56 PM

Genmab A/S Share Capital Reduction

Genmab
Regulatory press release4/14/2026, 2:44 PM

Major Shareholder Announcement

Genmab
Regulatory press release4/14/2026, 10:22 AM

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026

Genmab
Press release4/13/2026, 1:35 PM

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Genmab
Regulatory press release4/1/2026, 7:19 PM

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Genmab
Regulatory press release4/1/2026, 7:24 AM

Major Shareholder Announcement

Genmab
Regulatory press release3/30/2026, 3:59 PM

Major Shareholder Announcement

Genmab
Regulatory press release3/19/2026, 6:21 PM

Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab
Regulatory press release3/19/2026, 2:05 PM

Passing of Genmab A/S’ Annual General Meeting

Genmab
Regulatory press release3/16/2026, 2:09 PM

Completion of Share Buy-back Program

Genmab
Regulatory press release3/9/2026, 2:01 PM

Transactions in Connection with Share Buy-back Program

Genmab